All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
The MM-003 clinical trial compared the use of pomalidomide plus either low- or high- dose dexamethasone, for the treatment of patients with relapsed and refractory (RR) Multiple Myeloma (MM), after failed treatment with bortezomib and lenalidomide. A favorable outcome was observed for pomalidomide plus low-dose dexamethasone. An updated analysis of patient outcome was assessed according to treatment history and depth of response, and was published in Haematologica in June 2015, by Jesus San Miguel from Clinica Universidad de Navarra, CIMA, Pamplona, Spain and colleagues. This secondary analysis (at data cut-off September 1st, 2013) assessed progression-free survival (PFS), overall survival (OS), overall response rate (ORR; the proportion of patients achieving a PR or better), time to progression (TTP), duration of response (DOR), safety, and quality of life. Study design and treatment regimen are detailed in a previous MMHub article.
Data are given as: POM+LoDEX vs POM+HiDEX:
These updated results with a longer follow-up period confirmed a significant PFS benefit for patients treated with pomalidomide plus low-dose dexamethasone, and this effect carried through into assessment for depth of response, regardless of patient age, prior treatment or cytogenetic risk status. Therefore, pomalidomide plus low-dose dexamethasone is a beneficial treatment pathway for patients with RRMM, for whom other therapies have been exhausted.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox